gip/glp-1 receptor agonist drugs list A of recently developed GLP-1R/GIPR dual agonists. 45 GLP-1 and Dual GIP/GLP-1 Agonists

In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday

J.PeifferJ

FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee Meeting Provides the official agenda, substances and uses evaluated, meeting materials, and archived broadcasts

What Is Included